ABOUT US Our focus on glycogen synthase kinase-3β (the enzyme GSK-3β) has led to the development of the therapeutic candidate elraglusib (formerly known as 9-ING-41). Elraglusib has shown tremendous potential in the treatment of many different cancers when used alone or in combination with other types of cancer therapies, including chemotherapy and immune modulators such […]
THE PASSION TO PURSUE MORE Who we are Actuate aims to give patients with hard-to-treat cancers the opportunity to live longer and better with the potential capacity to slow, stop, or shrink tumors, with minimal adverse effects. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets multiple molecular pathways in cancer that are involved in promoting
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate
